Share this article on:

New Treatments in Neuro-Ophthalmology: The Role for Evidence

Kupersmith, Mark J. MD; Miller, Neil R. MD; Levin, Leonard A. MD, PhD

Journal of Neuro-Ophthalmology: March 2017 - Volume 37 - Issue 1 - p 1–2
doi: 10.1097/WNO.0000000000000482
Editorial

Icahn School of Medicine at Mount Sinai and New York Eye and Ear Infirmary (MKJ), New York, New York

Wilmer Eye Institute, Johns Hopkin School of Medicine (NRM), Baltimore, Maryland

McGill University Faculty of Medicine (LAL), Montreal, Quebec, and University of Wisconsin, Madison, Wisconsin.

Address correspondence to Mark J. Kupersmith, MD, Icahn School of Medicine at Mount Sinai and New York Eye and Ear Infirmary, New York, NY 10019; E-mail: mkuper@chpnet.org

M. J. Kupersmith and N. R. Miller receive compensation from Quark Pharmaceuticals for the conduct of the QP1007 NAION treatment trial. L. A. Levin has served as a consultant on neuroprotection to Aerie, GSK, Inotek, Quark, and Regenera. The authors report no other conflicts of interest.

© 2017 by North American Neuro-Ophthalmology Society